Modified-release nicotinamide for the treatment of hyperphosphataemia in haemodialysis patients: 52-week efficacy and safety results of the phase 3 randomized controlled NOPHOS trial
Open Access
- 25 June 2022
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 38 (4), 982-991
- https://doi.org/10.1093/ndt/gfac206
Abstract
We previously reported that modified-release nicotinamide (NAMR) was superior to placebo in reducing serum phosphate concentrations over 12 weeks in a large cohort of haemodialysis patients with hyperphosphataemia. Here we report outcomes after 52 weeks of treatment. NOPHOS was a phase 3, international, randomized, controlled, double-blind trial with a parallel group design. NAMR (250–1500 mg/day) was investigated in comparison to placebo as an add-on therapy to an individual therapy with approved phosphate binders. In the intention-to-treat population (NAMR: n = 539; placebo: n = 183), serum phosphate was significantly lower in the NAMR group compared with the placebo group at week 24 (5.40 ± 1.55 versus 5.79 ± 1.37 mg/dl, P < .001) with a mean difference of −0.39 mg/dl [95% confidence interval (CI) −0.66 to −0.13], but was comparable between the groups at week 52 [mean difference −0.08 (95% CI −0.36–0.20)]. In the completer population (n = 358), statistical significance in favour of NAMR was reached at weeks 24 and 52. The treatment effect was reduced in patients with high baseline serum intact parathyroid hormone (iPTH) compared with patients with low baseline serum iPTH. Compliant patients in the NAMR group had a more pronounced and sustained reduction in serum phosphate than non-compliant patients. NAMR treatment was associated with a significantly increased risk of thrombocytopenia, pruritus, anaemia, and diarrhoea. Herpes zoster occurred exclusively in patients randomized to NAMR. NAMR combined with phosphate binders significantly reduced serum phosphate over the first 24 weeks of treatment, but the treatment effect was not maintained up to week 52. Non-compliance may have contributed to reduced long-term efficacy. Several newly identified safety signals warrant further evaluation.Funding Information
- MEDICE Arzneimittel Pütter GmbH & Co.
This publication has 50 references indexed in Scilit:
- COSMOS: the dialysis scenario of CKD–MBD in EuropeNephrology Dialysis Transplantation, 2012
- Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis populationNephrology Dialysis Transplantation, 2010
- Intestinal Npt2b Plays a Major Role in Phosphate Absorption and HomeostasisJournal of the American Society of Nephrology, 2009
- Mortality Risk for Dialysis Patients With Different Levels of Serum Calcium, Phosphorus, and PTH: The Dialysis Outcomes and Practice Patterns Study (DOPPS)American Journal of Kidney Diseases, 2008
- A Randomized, Double-Blind, Placebo-Controlled Trial of Niacinamide for Reduction of Phosphorus in Hemodialysis PatientsClinical Journal of the American Society of Nephrology, 2008
- Hyperphosphatemia of chronic kidney diseaseKidney International, 2008
- A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal diseaseBMC Nephrology, 2008
- Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patientsKidney International, 2006
- Cox's Regression Model for Counting Processes: A Large Sample StudyThe Annals of Statistics, 1982
- Studies on nicotinic acid interaction with bilirubin metabolismDigestive Diseases and Sciences, 1979